UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 28, 2023
Apellis Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-38276 | 27-1537290 | ||
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
100 Fifth Avenue Waltham, MA |
02451 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (617)977-5700
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box bel…
Read the full article at: https://www.marketscreener.com/quote/stock/APELLIS-PHARMACEUTICALS-38607086/news/Apellis-Pharmaceuticals-Costs-Associated-with-Exit-Disposal-Form-8-K-44720751/